Roth Capital’s healthcare analyst Joseph Pantginis weighed in with a favorable report on Peregrine Pharmaceuticals (NASDAQ:PPHM), after the company released its fiscal fourth-quarter and full-year 2015 results, posting EPS …
Peregrine Pharmaceuticals (NASDAQ:PPHM), a biopharmaceutical company focused on developing novel investigational products that help harness the body’s own immune system to fight cancer, …
Roth Capital analyst Joseph Pantginis weighed in with some commentary on Peregrine Pharmaceuticals (NASDAQ:PPHM) after the company generated a preclinical data set supporting the immune …
In a research report issued today, MLV analyst Thomas Yip maintained a Buy rating on Peregrine Pharma (NASDAQ:PPHM) with a price target of …
In a research report issued today, MLV analyst Thomas Yip reiterated a Buy rating on Peregrine Pharmaceuticals (NASDAQ:PPHM) with a $3.50 price target, after …
Peregrine Pharmaceuticals (NASDAQ:PPHM), a biopharmaceutical company focused on oncology and the treatment of lung and breast cancers through the development of bavituximab, a …
Peregrine Pharmaceuticals (NASDAQ:PPHM), a biopharmaceutical company focused on advancing bavituximab, a novel immuno-oncology agent in Phase III development for the treatment of lung cancer, …
Peregrine Pharmaceuticals (NASDAQ:PPHM), a biopharmaceutical company focused on advancing bavituximab, a novel immuno-oncology (I-O) agent in Phase III development for the treatment of lung …
Peregrine Pharmaceuticals (NASDAQ:PPHM) announced the presentation of data from preclinical studies demonstrating the combination of phosphatidylserine (PS) blockade with anti-PD-1 or anti-CTLA-4 immune …
In a research report released Friday, MLV & Co. analyst Thomas Yip reiterated a Buy rating on Peregrine Pharmaceuticals (NASDAQ:PPHM) with a $3.
